Overexpression of murine fizzy-related (fzr) increases natural killer cell-mediated cell death and suppresses tumor growth

Blood

Volumn 96, Issue 1, 2000, Pages 259-263

  Wang, Chun Xiang ^a   Fisk, Bernard C ^a   Wadehra, Madhuri ^a   Su, Helen ^a   Braun, Jonathan ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; B CELL LYMPHOMA; CANCER INHIBITION; CELL INTERACTION; CONTROLLED STUDY; GENE OVEREXPRESSION; HOST RESISTANCE; HYBRIDIZATION; LYMPHOMA CELL LINE; MOUSE; NATURAL KILLER CELL MEDIATED CYTOTOXICITY; NONHUMAN; PRIORITY JOURNAL;

EID: 0034235317     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v96.1.259.013k36_259_263     Document Type: Article

References (45)

1. Alexander WS, Adams JM, Cory S. Oncogene cooperation in lymphocyte transformation: malignant conversion of E mu-myc transgenic pre-B cells in vitro is enhanced by v-H-ras or v-raf but not v-abl. Mol Cell Biol. 1989;9:67.
2. Alexander WS, Bernard O, Cory S, Adams JM. Lymphomagenesis in Emu-myc transgenic mice can involve ras mutations. Oncogene. 1989;4: 575.
3. Blyth K, Terry A, O'Hara M, et al. Synergy between a human c-myc transgene and p53 null genotype in murine thymic lymphomas: contrasting effects of homozygous and heterozygous p53 loss. Oncogene. 1995;10:1717.
4. Elson A, Deng C, Campos-Torres J, Donehower LA, Leder P. The MMTV/c-myc transgene and p53 null alleles collaborate to induce T-cell lymphomas, but not mammary carcinomas in transgenic mice. Oncogene. 1995;11:181.
5. Fanidi A, Harrington EA, Evan GI. Cooperative interaction between c-myc and bcl-2 proto-oncogenes. Nature. 1992;359:554.
6. Strasser A, Harris AW, Bath ML, Cory S. Novel primitive lymphoid tumours induced in transgenic mice by cooperation between myc and bcl-2. Nature. 1990;348:331.
7. Allen JD, Verhoeven E, Domen J, van der Valk M, Berns A. Pim-2 transgene induces lymphoid tumors, exhibiting potent synergy with c-myc. Oncogene. 1997;15:1133.
8. Scheijen B, Jonkers J, Acton D, Berns A. Characterization of pal-1, a common proviral insertion site in murine leukemia virus-induced lymphomas ot c-myc and Pim-1 transgenic mice. J Virol. 1997;71:9.
9. van der Lugt NM, Domen J, Verhoeven E, et al. Proviral tagging in E mu-myc transgenic mice lacking the Pim-1 proto-oncogene leads to compensatory activation of Pim-2. EMBO J. 1995;14: 2536.
10. Felsher DW, Denis KA, Weiss D, Ando DT, Braun J. A murine model for B-cell lymphomagenesis in immunocompromised hosts: c-myc-rearranged B-cell lines with a premalignant phenotype. Cancer Res. 1990;50:7042.
11. Felsher DW, Rhim SH, Braun J. A murine model for B-cell lymphomagenesis in immunocompromised hosts: natural killer cells are an important component of host resistance to premalignant B-cell lines. Cancer Res. 1990;50:7050.
12. Diatchenko L, Lau YF, Campbell AP, et al. Suppression subtractive hybridization: a method for generating differentially regulated or tissue-specific cDNA probes and libraries. Proc Natl Acad Sci USA 1996;93:6025.
13. Sigrist SJ, Lehner CF. Drosophila fizzy-related down-regulates mitotic cyclins and is required for cell proliferation arrest and entry into endocycles. Cell. 1997;90:671.
14. Braun J, Ando D, Denis K, et al. Generation and characterization of murine Ly-1 (CD5) B-cell lines. In: Witte ON, Klinman N, Howard MC, eds. B-Cell Development: UCLA Symposia in Molecular and Cellular Biology. New York, Alan R Liss; 1988:55.
15. Chenchik A, Diatchenko L, Mogadam F, Tarabykin V, Lukyanov S, Siebert PD. Full-length cDNA cloning and determination of mRNA 5′ and 3′ ends by amplification of adaptor-ligated cDNA. Cancer Res. 1996;21:526.
16. Kingston RE. Introduction of DNA into Mammalian Cells. In: Ausubel FM, Brent R, Kingston RE, Moore DD, Seidman JG, Smith JA, Struhl K, eds. Current Protocols in Molecular Biology, Vol 1. New York; John Wiley & Sons; 1997:9.1.4-9.1.7.
17. Altschul SF, Madden TL, Schaffer AA, et al. Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. Nucleic Acids Res. 1997;25:3389.
18. Sigrist S, Jacobs H, Stratmann R, Lehner CF. Exit from mitosis is regulated by Drosophila fizzy and the sequential destruction of cyclins A, B and B3. EMBO J. 1995;14:4827.
19. Weinstein J. Cell cycle-regulated expression, phosphorylation, and degradation of p55Cdc. A mammalian homolog of CDC20/Fizzy/slp1. J Biol Chem. 1997;272:28501.
20. Shirayama M, Zachariae W, Ciosk R, Nasmyth K. The Polo-like kinase Cdc5p and the WD-repeat protein Cdc20p/fizzy are regulators and substrates of the anaphase promoting complex in Saccharomyces cerevisiae. EMBO J. 1998;17: 1336.
21. Lambright DG, Sondek J, Bohm H, Skiba NP, Hamm HE, Sigler PB. The 2.0 A crystal structure of a heterotrimeric G protein. Nature. 1996;379: 311.
22. Neer EJ, Schmidt CJ, Nambudripad R, Smith TF. The ancient regulatory-protein family of WD-repeat proteins. Nature. 1994;371:297.
23. Kitamura K, Maekawa H, Shimoda C. Fission yeast Ste9, a homolog of Hct1/Cdh1 and Fizzy-related, is a novel negative regulator of cell cycle progression during G1-phase. Mol Biol Cell. 1998;9:1065.
24. Visintin R, Prinz S, Amon A. CDC20 and CDH1: a family of substrate-specific activators of APC-dependent proteolysis. Science. 1997;278:460.
25. Zachariae W, Schwab M. Nasmyth K, Seufert W. Control of cyclin ubiquitination by CDK-regulated binding of Hct1 to the anaphase promoting complex. Science. 1998;282:1721.
26. Kallio M, Weinstein J, Daum JR, Burke DJ, Gorbsky GJ. Mammalian p55CDC mediates association of the spindle checkpoint protein Mad2 with the cyclosome/anaphase-promoting complex, and is involved in regulating anaphase onset and late mitotic events. J Cell Biol. 1998;141:1393.
27. Kao CT, Lin M, O'Shea-Greenfield A, Weinstein J, Sakamoto KM. Over-expression of p55Cdc inhibits granulocyte differentiation and accelerates apoptosis in myeloid cells. Oncogene. 1996;13: 1221.
28. Lin M, Mendoza M, Kane L, Weinstein J, Sakamoto KM. Analysis of cell death in myeloid cells inducibly expressing the cell cycle protein p55Cdc. Exp Hematol. 1998;26:1000.
29. Matsumoto T. A fission yeast homolog of CDC20/p55CDC/Fizzy is required for recovery from DNA damage and genetically interacts with p34cdc2. Mol Cell Biol. 1997;17:742.
30. Fang G, Yu H, Kirschner MW. The checkpoint protein MAD2 and the mitotic regulator CDC20 form a ternary complex with the anaphase-promoting complex to control anaphase initiation. Genes Dev. 1998;12:1871.
31. Robertson MJ, Ritz J. Biology and clinical relevance of human natural killer cells. Blood. 1990; 76:2421.
32. de Moissac D, Mustapha S, Greenberg AH, Kirshenbaum LA. Bcl-2 activates the transcription factor NFkappaB through the degradation of the cytoplasmic inhibitor IkappaBalpha. J Biol Chem. 1998;273:23946.
33. Drexler HC. Activation of the cell death program by inhibition of proteasome function. Proc Natl Acad Sci USA. 1997;94:855.
34. Herrmann JL, Briones FJ, Brisbay S, Logothetis CJ, McDonnell TJ. Prostate carcinoma cell death resulting from inhibition of proteasome activity is independent of functional Bcl-2 and p53. Oncogene. 1998;17:2889.
35. Meriin AB, Gabai VL, Yaglom J, Shifrin VI, Sherman MY. Proteasome inhibitors activate stress kinases and induce Hsp72. Diverse effects on apoptosis. J Biol Chem 1998;273:6373.
36. Lanier LL. NK cell receptors. Annu Rev Immunol. 1998;16:359.
37. Borrego F, Ulbrecht M, Weiss EH, Coligan JE, Brooks AG. Recognition of human histocompatibility leukocyte antigen (HLA)-E complexed with HLA class I signal sequence-derived peptides by CD94/NKG2 confers protection from natural killer cell-mediated lysis. J Exp Med. 1998;187:813.
38. Lee N, Llano M, Carretero M, et al. HLA-E is a major ligand for the natural killer inhibitory receptor CD94/NKG2A [see comments]. Proc Natl Acad Sci USA. 1998;95:5199.
39. Llano M, Lee N, Navarro F, et al. HLA-E-bound peptides influence recognition by inhibitory and triggering CD94/NKG2 receptors: preferential response to an HLA-G-derived nonamer. Eur J Immunol. 1998;28:2854.
40. Malnati MS, Peruzzi M, Parker KC, et al. Peptide specificity in the recognition of MHC class I by natural killer cell clones. Science. 1995;267:1016.
41. Su RC, Kung SK, Gariepy J, Barber BH, Miller RG. NK cells can recognize different forms of class I MHC. J Immunol. 1998;161:755.
42. Waldenstrom M, Sundback J, Olsson-Alheim MY, Achour A, Karre K. Impaired MHC class I (H-2Dd)-mediated protection against Ly-49A+ NK cells after amino acid substitutions in the antigen binding cleft. Eur J Immunol. 1998;28:2872.
43. Wang Z, Arienti F, Parmiani G, Ferrone S. Induction and functional characterization of beta2-microglobulin (beta2-mu)-free HLA class I heavy chains expressed by beta2-mu-deficient human FO-1 melanoma cells. Eur J Immunol. 1998;28: 2817.
44. Kisselev AF, Akopian TN, Woo KM, Goldberg AL. The sizes of peptides generated from protein by mammalian 26 and 20 S proteasomes. Implications for understanding the degradative mechanism and antigen presentation. J Biol Chem. 1999;274:3363.
45. York IA, Rock KL. Antigen processing and presentation by the class I major histocompatibility complex. Annu Rev Immunol. 1996;14:369.